Publications

• real-world use of teriflunomide in Germany and changes in treatment patterns over time

  B.-A. Kallmann, G. Zu Eulenburg, J.S. Kullmann, M. Mäurer

  PMID: 38808094 Show Details link to full text
  Study

  TAURUS-MS II

  Year

  2024

  Keywords

  • multiple sclerosis

• Design and Rationale of MYOFLAME-19 RCT: MYOcardial protection to reduce inFLAMmatory heart disease due to COVID-19 Infection using CMR Endpoints

  V. O. Puntmann , D. Beitzke, A. Kammerlander, I. Voges, D. D. Gabbert, M. Doerr, B. Chamling, B. Bozkurt, J. C. Kaski, E. Spatz, E. Herrmann, G. Rohde, P. DeLeuw, L. Taylor, C. Windemuth-Kieselbach, C. Harz, M. Santiuste, L. Schoeckel, J. Hirayama, P. C. Taylor, C. Berry, E. Nagel

  PMID: 39481808 Show Details link to full text
  Study

  MYOFLAME-19

  Year

  2024

  Keywords

  • cardiovascular
  • COVID-19

• The RANKL inhibitor denosumab in combination with dual checkpoint inhibition is associated with increased CXCL-13 serum concentrations

  Schaper-Gerhardt, K., Gutzmer, R., Angela, Y., Zimmer, L., Livingstone, E., Schadendorf, D., Hassel, J. C., Weishaupt, C., Remes, B., Kubat, L., Spassova, I., Becker, J. C.

  PMID: 38479119 Show Details link to full text
  Study

  BONEMET

  Year

  2024

  Keywords

  • immunotherapy
  • melanoma

• Adjuvant immunotherapy with nivolumab versus observation in completely resected Merkel cell carcinoma (ADMEC-O): disease-free survival results from a randomised, open-label, phase 2 trial

  Prof Jürgen C Becker, MD PhD; Prof Selma Ugurel, MD; Prof Ulrike Leiter, MD; Prof Friedegund Meier, MD; Prof Ralf Gutzmer, MD; Prof Sebastian Haferkamp, MD; Lisa Zimmer, MD; Elisabeth Livingstone, MD; Prof Thomas K Eigentler, MD; Prof Axel Hauschild, MD: Felix Kiecker, MD; Prof Jessica C Hassel, MD; Peter Mohr, MD; Michael Fluck, MD; Ioannis Thomas, MD; Marlene Garzarolli, MD; Imke Grimmelmann, MD; Konstantin Drexler, MD; Alexandra N Spillner, PhD; Sebastian Eckhardt, MS; Prof Dirk Schadendorf, MD

  PMID: Show Details link to full text
  Study

  ADMEC-O

  Year

  2023

  Keywords

  • immunotherapy
  • nivolumab
  • Merkel cell carcinoma

• Early switch from run-in treatment with vemurafenib plus cobimetinib to atezolizumab after 3 months leads to rapid loss of tumour control in patients with advanced BRAFV600-positive melanoma: The ImmunoCobiVem phase 2 randomised trial

  E. Livingstone; H. Gogas; L. Kandolf-Sekulovic; F. Meier; T.K. Eigentler; M. Ziemer; P.A.M. Terheyden; A.H. Gesierich; R.A. Herbst; K.C. Kähler; D.C. Ziogas; Z. Mijuskovic; M. Garzarolli; C. Garbe; A. Roesch; S. Ugurel; R. Gutzmer; J.J. Grob; F. Kiecker; J. Utikal; C. Windemuth-Kieselbach; S. Eckhardt; L. Zimmer; D. Schadendorf

  PMID: 10.1016/j.ejca.2023.112941 Show Details link to full text
  Study

  ImmunoCobiVem

  Year

  2023

  Keywords

  • melanoma

• Breast Cancer and Genetic BRCA1/2 Testing in Routine Clinical Practice: Why, When and For Whom?

  Michael P. Lux, Peter A. Fasching

  PMID: 10.1055/a-1929-2629 Show Details link to full text
  Study

  Year

  2023

  Keywords

  • breast cancer

• New Systemic Therapy Strategies for HER2-Positive Metastatic Breast Carcinoma

  Maggie Banys-Paluchowski

  PMID: 10.1055/a-1850-9512 Show Details link to full text
  Study

  Year

  2023

  Keywords

  • HER2
  • breast cancer

• A Prospective Study to Evaluate the Impact of Golimumab Therapy on Work Productivity and Activity, and Quality of Life in Patients with Rheumatoid Arthritis, Psoriasis Arthritis and Axial Spondyloarthritis in a Real Life Setting in AUSTRIA. The GO-ACTIVE

  C. Dejaco, T. Mueller, O. Zamani, U. Kurtz, S. Egger, J. Resch-Passini, A. Totzauer, B. Yazdani-Biuki, T. Schwingenschloegl, P. Peichl, A. Kraus, G. W. Naerr

  PMID: 35721062 Show Details link to full text
  Study

  GO ACTIVE

  Year

  2022

  Keywords

  • rheumatoid arthritis
  • psoriatic arthritis
  • axial spondyloarthritis
  • golimumab
  • QoL
  • WPAI

• Incidental Pulmonary Nodules - What Do We Know in 2022

  Gerald Schmid-Bindert, Jens Vogel-Claussen, Sylvia Gütz, Joana Fink, Hans Hoffmann, Martin E. Eichhorn, Felix J.F. Herth

  PMID: 36228594 Show Details link to full text
  Study

  Year

  2022

  Keywords

  • lung cancer

• Optimizing therapy sequence to prevent patient attrition in EGFR mutation-positive advanced or metastatic NSCLC

  J. Roeper, S. Kurz, C. Grohé, F. Griesinger

  PMID: 33094641 Show Details link to full text
  Study

  Year

  2021

  Keywords

  • EGFR
  • NSCLC
  • tyrosine kinase inhibitor
  • oncology